6-(HEPTAN-3-YL)-4-METHYL-2H-PYRAN-2-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VMHGAIDIOHDNRR-UHFFFAOYSA-N
Smiles	CCCCC(CC)C1=CC(=CC(=O)O1)C
InChI	InChI=1S/C13H20O2/c1-4-6-7-11(5-2)12-8-10(3)9-13(14)15-12/h8-9,11H,4-7H2,1-3H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H20O2
Molecular Weight	208.3
AlogP	3.95
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	5.0
Polar Surface Area	26.3
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	15.0

Assay Description	Organism	Bioactivity
Antifungal activity against Pythium debaryanum assessed as inhibition of fungal growth	Pythium debaryanum	150.97 ug ml-1
Antifungal activity against Pythium aphanidermatum assessed as inhibition of fungal growth	Pythium aphanidermatum	276.96 ug ml-1
Antifungal activity against Macrophomina phaseolina assessed as inhibition of fungal growth	Macrophomina phaseolina	261.94 ug ml-1
Antifungal activity against Rhizoctonia bataticola assessed as inhibition of fungal growth	Rhizoctonia bataticola	303.13 ug ml-1
Antifungal activity against Rhizoctonia solani Nees assessed as inhibition of fungal growth	Rhizoctonia solani	183.66 ug ml-1
Antifungal activity against Athelia rolfsii assessed as inhibition of fungal growth	Athelia rolfsii	349.0 ug ml-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2252911
PubChem	21520156
SureChEMBL	SCHEMBL11858167

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).